Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity

Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency

(2022) Cindy X. Cai et al.   Scientific Reports

Modulating tyrosine sulfation of recombinant antibodies in CHO cell culture by host selection and sodium chlorate supplementation

(2021) Ren Liu et al.   Biotechnology Journal

Oxidation and Deamidation of Monoclonal Antibody Products: Potential Impact on Stability, Biological Activity, and Efficacy

(2021) Surbhi Gupta et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

A single molecular descriptor to predict solution behavior of therapeutic antibodies

(2020) Jonathan S. Kingsbury et al.   Science Advances

Characterization and prediction of positional 4-hydroxyproline and sulfotyrosine, two post-translational modifications that can occur at substantial levels in CHO cells-expressed biotherapeutics

(2019) Oksana Tyshchuk et al.   mAbs

Distinguishing Sulfotyrosine Containing Peptides from their Phosphotyrosine Counterparts Using Mass Spectrometry

(2018) Guangming Chen et al.   JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY

Isotonic Concentrations of Excipients Control the Dimerization Rate of a Therapeutic Immunoglobulin G1 Antibody During Refrigerated Storage Based on Their Rank Order of Native-State Interaction

(2018) Douglas D. Banks et al.   PROTEIN SCIENCE

Engineering therapeutic bispecific antibodies using CrossMab technology

(2018) Christian Klein et al.   METHODS

Characterization of a novel modification of a CHO-produced mAb: Evidence for the presence of tyrosine sulfation

(2017) Jia Zhao et al.   mAbs

Next generation antibody drugs: pursuit of the 'high-hanging fruit'

(2017) Paul J. Carter et al.   NATURE REVIEWS DRUG DISCOVERY

Comparison of surface plasmon resonance binding curves for characterization of protein interactions and analysis of screening data

(2016) Robert Karlsson et al.   ANALYTICAL BIOCHEMISTRY

Cysteinylation of a monoclonal antibody leads to its inactivation

(2016) Troy McSherry et al.   mAbs

The use of CrossMAb technology for the generation of bi- and multispecific antibodies

(2016) Christian Klein et al.   mAbs

CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors

(2016) Marina Bacac et al.   OncoImmunology

The second virial coefficient as a predictor of protein aggregation propensity: A self-interaction chromatography study

(2015) A. Quigley et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Quantitative Evaluation of Colloidal Stability of Antibody Solutions using PEG-Induced Liquid–Liquid Phase Separation

(2014) Ying Wang et al.   MOLECULAR PHARMACEUTICS

Native-State Solubility and Transfer Free Energy as Predictive Tools for Selecting Excipients to Include in Protein Formulation Development Studies

(2012) Douglas D. Banks et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

General strategy for the generation of human antibody variable domains with increased aggregation resistance

(2012) K. Dudgeon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Fragmentation of monoclonal antibodies

(2011) Josef Vlasak et al.   mAbs

Predicting sulfotyrosine sites using the random forest algorithm with significantly improved prediction accuracy

(2009) Zheng Yang   BMC BIOINFORMATICS

Incorporating support vector machine for identifying protein tyrosine sulfation sites

(2009) Wen-Chi Chang et al.   JOURNAL OF COMPUTATIONAL CHEMISTRY

Tyrosine sulfation: an increasingly recognised post-translational modification of secreted proteins

(2009) Martin J. Stone et al.   New Biotechnology

Removal of Cysteinylation from an Unpaired Sulfhydryl in the Variable Region of a Recombinant Monoclonal IgG1 Antibody Improves Homogeneity, Stability, and Biological Activity

(2007) Douglas D. Banks et al.   JOURNAL OF PHARMACEUTICAL SCIENCES